SAN DIEGO (AP) — Orexigen Therapeutics Inc. said Monday it is in discussions with the Food and Drug Administration about speeding up a regulatory review of Orexigen's obesity drug Contrave.
Shares rose 30 cents, or 4.9 percent, to $6.45 in premarket trading.
Orexigen is looking for ways to quicken the application process for Contrave, and the company said the FDA is open to discussing options. The FDA approved two other obesity treatments in June and July, and Orexigen is looking to get Contrave on the market as soon as possible. The company had said it hoped to file for marketing approval of Contrave in late 2013, and a standard FDA review would take another 10 months.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
